Kymab Announces Clinical Update on its promising new antibody KY1005 for treatment of autoimmune diseases

  • The third dosing cohort has been completed and 24 patients have now been dosed.

  • KY1005-CT01 clinical study is targeting a total enrollment of 88.

  • Primary completion is expected in 1H 2018.

  • The study is a single and multiple ascending dose, placebo-controlled, double-blind, Phase 1 study to evaluate the safety and tolerability of KY1005 in healthy volunteers and patients with a mild-to-moderate immune system disease (psoriasis).

  • KY1005 is an antagonist of OX40-Ligand (OX40L) with the potential to treat a number of immune and inflammatory disorders (autoimmune diseases).

Kymab, an emerging biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs, announces today that KY1005, its novel human antibody therapeutic, has successfully completed dosing of the 24th subject in its first clinical study.